In addition, Gal-3 can be used as a biomarker of renal failure and it is present in pulmonary and hepatic fibrosis, making it useful as a specific biomarker of PAH only when these comorbidities are not present (256). Here, LGALS3 is linked to Hepatic fibrosis.